002020 Zhejiang Jingxin Pharmaceutical
- 10.88
- -0.12-1.09%
Zhejiang Jingxin Pharmaceutical News
Express News | A-share restricted shares to be lifted at a glance: 20.255 billion yuan of restricted shares in market cap will be lifted today.
Zhejiang Jingxin Pharmaceutical (002020.SZ): 67.5676 million restricted shares will be listed for trading from September 11th.
Zhejiang Jingxin Pharmaceutical (002020.SZ) issued a notification regarding the listing and circulation of privately placed restricted shares in 2020.
Zhejiang Jingxin Pharmaceutical (002020) company brief report: steady performance growth, continuous promotion of innovative drug commercialization.
Event: The company has released its 2024 interim report, achieving revenue of 2.15 billion yuan (+11.02%) and net income attributable to shareholders of listed companies of 0.402 billion yuan (+27.28%), after deducting non-recurring items, attributable to listed
Zhejiang Jingxin Pharmaceutical (002020): Steady Growth in Performance, Achievements of Business Reform Have Been Seen.
The performance is steadily improving, and the profitability continues to rise. The company released its 2024 interim report, with both revenue and net income achieving double-digit growth. In the first half of 2024, the company achieved revenue of 2.15 billion yuan (a year-on-year increase of +11.02%).
Zhejiang Jingxin Pharmaceutical (002020.SZ): JX11502MA capsules and Kangfu Xin enteric capsules II clinical trials are underway.
On August16th, www.glinfo.com reported that on August 15th, 2024, Zhejiang Jingxin Pharmaceutical (002020.SZ) stated during a specific object investigation that clinical trials of JX11502MA capsules and KefuXin enteric-coated capsules II are underway; JX2105 capsules have received clinical trial approvals, and Phase I clinical trials are progressing smoothly; more than 10 other research projects are being carried out in an orderly manner.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's sales expenses in the first half of the year were 0.384 billion, a year-on-year decrease of 3.63%.
On August 15, 2024, during a specific research conducted by certain parties, Zhejiang Jingxin Pharmaceutical (002020.SZ) reported a sales expense of 0.384 billion, a 3.63% YoY decrease, and a 2.72 percentage point decrease in sales expense ratio. The company has achieved a continuous reduction in sales expenses in recent years, partly due to the company's emphasis on improving sales productivity, and partly due to the adjustment of the internal structure of the sales expenses and the accurate investment in cost control. With the market promotion of Daltasone, some additional expenses are inevitable, but the company will strive to control the sales expense ratio in the hope of keeping it low.
Zhejiang Jingxin Pharmaceutical (002020): Steady growth in performance, initial results of marketing reform are showing.
Event: The company released its 2024 interim report. In the first half of 2024, Zhejiang Jingxin Pharmaceutical achieved revenue of 2.15 billion (+11.02%) and net income attributable to the parent company of 0.402 billion (+27.28%), with non-net income attributable to the parent company of 3, and net income of 0.402 billion (+27.28%).
Express News | Zhejiang Jingxin Pharmaceutical: The hospitalization rhythm of Daratumumab is in line with expectations, with a planned sales of over 40 million yuan this year.
Zhejiang Jingxin Pharmaceutical (002020): Q2 performance exceeds expectations, and the finished drug market continues to exert efforts outside the hospital.
Event: The company released its 2024 interim report. In H1 2024, the company achieved revenue of 2.15 billion yuan, an increase of 11.02% year-on-year. Net income attributable to the parent was 0.402 billion yuan, an increase of 27.28% year-on-year.
Zhejiang Jingxin Pharmaceutical: Half-year report for the year 2024.
Zhejiang Jingxin Pharmaceutical: Summary of Half-Year Report in 2024.
Express News | Zhejiang Jingxin Pharmaceutical: net income increased by 27.28% in the first half of the year.
Zhejiang Jingxin Pharmaceutical(002020.SZ): Currently, the centralized procurement covers only generic drugs.
On August 8th, Jingsin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the current centralized procurement covers only generic drugs. The differences in sales of innovative drugs are related to diseases, indications and so on. As the company's first innovative drug, we have equipped the best resources for the sales of Jingnoning. At the beginning of the launch, we focused on hospitalization and academic promotion, hoping to lay a solid foundation for future sales growth.
Zhejiang Jingxin Pharmaceutical (002020.SZ): Shandong Jingxin's Phase 1 project has started trial production.
Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform on July 30th that Shandong Jingxin's Phase 1 project has begun trial production. The purpose of the project implementation is to further improve the company's active pharmaceutical ingredient industry chain and contribute to the cost reduction and efficiency improvement of existing active pharmaceutical ingredient production. The short-term products will mainly supply Shaoxing Jingxin, and the export proportion will gradually increase in the future according to the market situation.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The admission and sales of Jinkening are proceeding in an orderly manner.
Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor communication platform on July 3 that the hospitalization and sales of Jinnuoning are proceeding in an orderly manner. The company's current operational status is normal. Please pay attention to the periodic reports for specific company business data.
Zhejiang Jingxin Pharmaceutical (002020.SZ): preparing materials for the upcoming medical insurance negotiations for Jinnuoning.
Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform on July 3rd that the company is preparing materials for the upcoming medical insurance negotiation for Jinnuoning. Currently, the company's other products are not involved in medical insurance.
Zhejiang Jingxin Pharmaceutical Gets European Certificate for Animal Antibiotic
Express News | Zhejiang Jingxin Pharmaceutical: Its subsidiary Enrofloxacin Active Pharmaceutical Ingredient obtains the CEP certificate in Europe.
Express News | Pacific Securities: The export of generic drugs is expected to open up a growth ceiling.
Jingxin Pharmaceutical (002020.SZ): The artificial large blood vessel project has now entered the small-scale human trial stage
Gelonghui, May 30丨Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that the company's artificial large blood vessel project has now entered the small-scale human trial stage. The time to market also depends on the progress of testing and other related work.
Analysis
Price Target
No Data
